UniPhar
Uniphar plc is an Irish diversified healthcare services group operating pharmaceutical and medical device distribution, clinical trial supply, managed access programs, and a retail pharmacy network, serving 200+ manufacturers and 160+ countries across Europe, North America, APAC, and MENA.
- Company typePublic
- Founded1994
- HeadquartersDublin, Ireland
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What UniPhar does
Uniphar plc is an Irish diversified healthcare services group listed on AIM and Euronext Growth (ticker: UPR), headquartered in Dublin and founded in 1967 by community pharmacists. The company operates three core divisions: Uniphar Medtech (exclusive medical device distribution across 21 European markets), Uniphar Pharma (global pharmaceutical sourcing, managed access programs, clinical trial supply, and commercialization services), and Supply Chain + Retail (Ireland's market-leading pharmaceutical wholesaler serving 280+ retail pharmacy partners and 445+ network pharmacies across four symbol groups: Allcare, Hickey's, McCauley, and Life). Uniphar also runs medical affairs services (BestMSLs Group, acquired 2021) and pharmacy dispensing software (TouchStore, acquired January 2026), and supplies GMP/GDP-compliant clinical trial materials from facilities in Lelystad (Netherlands) and Raleigh (North Carolina).
The company's technology stack centres on digital distribution platforms rather than software products: a B2B e-commerce platform (Magento-based, with intelligent search and self-service) showing 143% online revenue growth from 2016 to 2019, a validated Quality Management System with ISO 9001:2015 certification across 70% of the organisation, integrated clinical trial supply chain platforms for comparator sourcing and packaging, and bespoke managed access / named patient program portals. The technology is functional infrastructure supporting the distribution and services franchise rather than a distinct AI/software product surface.
Uniphar's business model combines low-margin wholesale distribution (transaction-based revenue from pharma and medtech product flows) with higher-margin services including managed access programs, clinical trial supply, medical affairs outsourcing, and recurring retail pharmacy brand support. Revenue is generated through quote-based B2B contracts, multi-year manufacturer agreements (serving all top 10 global pharma companies and 7 of the top 10 medtech companies), and a network of channel partners across Europe, North America, APAC, and MENA. FY2025 revenue reached €3.1 billion (~11% YoY growth) with €457.7m gross profit and €130.9m EBITDA (~4.2% margin), and the group employs 3,589 people across Ireland, the UK, Benelux, the Nordics, and the United States.
UniPhar firmographics
Firmographics- Name
- UniPhar
- Legal name
- Uniphar Plc
- Website
- https://www.uniphar.ie
- Company type
- Public
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Uniphar plc is an Irish diversified healthcare services group operating pharmaceutical and medical device distribution, clinical trial supply, managed access programs, and a retail pharmacy network, serving 200+ manufacturers and 160+ countries across Europe, North America, APAC, and MENA.
- Ownership category
- akta.pro rank
UniPhar industry classification
Industry- Product category
- Pharmaceutical and Healthcare Distribution Services
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmacies and Drug Retailers (456110)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)
- akta.pro primary industry
- Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)
- akta.pro secondary industry
- Retail & Community Pharmacies (Chain/Independent) (HLAFALAA)
Keywords
Where UniPhar is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices6 records
Markets served
UniPhar business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Pharma & Medtech Distribution: Revenue generated from distributing pharmaceutical products and medical devices to pharmacies and hospitals across Ireland, Europe, and globally. Includes pre-wholesale and wholesale distribution services, as well as commercial and clinical services to pharma manufacturers.
- Retail Pharmacy Services: Revenue from four pharmacy symbol groups (Allcare, Hickey's, McCauley, Life) providing buying power, category management, and support services to 280+ independent pharmacy partners in Ireland.
- Product Access & Clinical Services: Global sourcing of unlicensed medicines, expanded access programs, clinical trial supply services, and pharma services provided to pharmaceutical and biotech manufacturers. Includes revenue from digital medical education platforms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B distribution and services — no public pricing |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels6 records
UniPhar product offering
Product offeringCore offering
UniPhar is a diversified healthcare services group distributing pharmaceutical products and medical devices across Europe, North America, APAC, and MENA. The company operates three core divisions: Uniphar Medtech (exclusive medical device distribution across 21 European markets), Uniphar Pharma (clinical trial supply, expanded access programs, and global pharma services), and Supply Chain + Retail (Irish wholesale pharmaceutical distribution and a network of 445+ retail pharmacies operating under the Allcare, Hickey's, McCauley, and Life brands).
Product overview
UniPhar is a diversified healthcare solutions company operating across three main divisions: Uniphar Medtech (medical device distribution across 21 markets), Uniphar Pharma (global pharmaceutical sourcing, product access, and commercialization services), and Supply Chain + Retail (wholesale distribution and retail pharmacy brands). The company operates retail pharmacy brands including Allcare Pharmacy Group, Hickey's Pharmacy, and McCauley Health & Beauty. UniPhar's business model centers on pharmaceutical and medical device distribution, supply chain management, and retail pharmacy operations rather than a software-as-a-platform architecture. The company has made multiple acquisitions including BModesto Group, McCauley Pharmacy Group, Durbin, PharmaSource, BestMSLs Group, and others to build out its healthcare distribution and services portfolio. As a pharmaceutical/healthcare distribution and retail company, UniPhar's offerings are product-based (pharmaceuticals, medical devices) and service-based (distribution, clinical services) rather than software products with modules.
Differentiator
Problem solved
Functional benefit
Brands
- Allcare Pharmacy Group: Pharmacy retail brand operating across Ireland.
- Hickey's Pharmacy Group
- McCauley Health & Beauty
- Life Pharmacy
- Durbin
- BestMSLs Group
- BModesto Group
Products and services
- Uniphar Medtech Exclusive distribution and commercial services for medical device manufacturers across 21 European markets. The service covers cardiology, orthopaedics, ophthalmology, and other specialties, leveraging field sales teams and regulatory expertise to support market access for medtech manufacturers.
- Uniphar Pharma
Quantifiable outcome
- 143% online revenue growth from 2016 to 2019 through B2B e-commerce platform adoption
- +6 more outcomes
Companies that use UniPhar
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
UniPhar technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
UniPhar partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- Orphan Therapeutics Accelerator (OTXL)minorUniphar joined the Orphan ClinDevNet network alongside OPIS, SK pharmteco, and TMC Pharma as a strategic partner providing clinical trial execution and UK/European regulatory and market access expertise. The network aims to overcome barriers that cause ultra-rare disease therapies to stall by providing a decentralized, outsourced infrastructure for development and commercialization.
- OPIS (Organon), SK pharmteco, TMC PharmaminorNetwork partners in Orphan ClinDevNet alongside Uniphar, providing expanded access programs, U.S.-based viral vector manufacturing, and UK/European regulatory and market access expertise for ultra-rare disease therapies.
- J-PharmacoreJoint management of global Phase III trial for nanvuranlat (JPH203) for second-line biliary tract cancer following alignment with the US FDA on the regulatory pathway. Uniphar Development (Uniphar's regulatory and clinical development division) jointly manages the pivotal study with J-Pharma, allowing the drug to proceed directly to Phase III without an additional Phase II trial. First patients already randomized.
- BMclinicalcoreStrategic merger between Uniphar | Clinical and BMclinical forming a unified global partner for clinical trial supply. The combined entity integrates comparator sourcing expertise with integrated logistics services including sourcing, packaging, labeling, storage, and distribution of clinical materials. Facilities in Lelystad (Netherlands) and Raleigh (North Carolina) serve Europe, North America, APAC, and MENA. Merger aims to streamline global supply chains and improve reliability for pharma and biotech partners.
- Citius OncologycoreExclusive distribution agreement for LYMPHIR (denileukin diftitox-cxdl) across designated Western and Eastern European territories through country-specific managed access programs. Uniphar handles market access and distribution activities while Citius Oncology supplies finished product. This marks Citius Oncology's third international distribution partnership, building on existing arrangements covering Southern Europe, the Balkans, Turkey, and the Middle East.
- Zevra TherapeuticscoreExclusive distribution agreement for MIPLYFFA (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) outside of Europe. The agreement supports patient access expansion and complements Zevra's US and EU regulatory strategies. MIPLYFFA is FDA approved and under review by the EMA.
- European Accessibility Act ComplianceminorUniphar is committed to making its website accessible in accordance with the European Accessibility Act (Directive 2019/882), aligning with WCAG 2.1 level AA guidelines.
- Top 10 Global Pharma Companies (all served)coreLongstanding distribution and service relationships with all of the world's top 10 pharmaceutical companies, providing supply chain, commercial, and clinical services across multiple geographies.
- Top 10 Medical Device Companies (7 of top 10 served)coreExclusive distribution agreements with some of the world's leading medical device manufacturers across 21 European markets for interventional cardiology, orthopaedics, ophthalmology, and other medical specialties.
- Monsoon ConsultingminorWeb accessibility consultancy engaged to conduct self-assessment of web pages using WAVE (Web Accessibility Evaluation Tool) and VoiceOver screenreader for European Accessibility Act compliance.
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
UniPhar competitors and assessment
Company assessmentDirect peers
- Celesio / McKesson Europe: One of Europe's largest pharmaceutical wholesalers and retail pharmacy operators, owned by McKesson. UniPhar CEO Ger Rabbette was previously Managing Director of Celesio's Movianto, making this the closest direct comparable in pharma wholesale and patient access services.
- Phoenix Group: European pharmaceutical wholesale and retail pharmacy group headquartered in Germany. Operates across multiple countries with both wholesale distribution and pharmacy retail banners — directly analogous to UniPhar's dual wholesale + retail pharmacy model in Ireland.
- Alliance Healthcare (Walgreens Boots Alliance): Wholesale distributor of pharmaceuticals and consumer healthcare products across Europe, owned by Walgreens Boots Alliance. Closely comparable to UniPhar Pharma's pre-wholesale, wholesale, and patient access distribution in European markets.
- IQVIA: Global clinical research, commercial, and clinical trial supply services provider serving pharma and biotech manufacturers. Closely comparable to UniPhar's clinical trial supply, managed access, and outsourced medical affairs (BestMSLs) capabilities serving the same enterprise customer base.
- PCI Pharma Services: Global contract development and manufacturing organization with strong clinical trial supply, packaging, and distribution capabilities. Closely comparable to UniPhar's combined BMclinical / Uniphar | Clinical platform for comparator sourcing, GMP/GDP-compliant trial materials supply across Europe and North America.
Broad incumbents
- McKesson Corporation: Global pharmaceutical distribution and healthcare services leader with North America Pharma Solutions and McKesson Europe. Comparable in pharma wholesale and specialty services, but operating at materially greater scale and geographic breadth than UniPhar.
- Cencora (formerly AmerisourceBergen): Top-tier US-based global pharmaceutical distributor with strong specialty distribution and consulting businesses (including PharmaLex and World Courier). Overlaps with UniPhar's pharma distribution, managed access, and clinical trial supply verticals at vastly larger scale.
- Walgreens Boots Alliance: Global pharmacy-led health and beauty retailer with both US retail pharmacy and European wholesale (Alliance Healthcare). Comparable to UniPhar's combination of Irish retail pharmacy brands (Allcare, Hickey's, Life, McCauley) and pharmaceutical distribution, although operating globally.
- Cardinal Health: US-based global pharmaceutical and medical product distributor with both pharma distribution and at-Home Solutions / medical segments. Overlaps with UniPhar's combined pharmaceutical and medical device distribution model, though at much greater scale and with primary US exposure.
- Henry Schein: Global distributor of medical, dental, and veterinary healthcare products serving office-based practitioners and ambulatory surgery centers. Comparable to UniPhar Medtech's exclusive medical device distribution across 21 European markets for cardiology, orthopaedics, and ophthalmology customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
UniPhar social profiles
Digital presenceUniPhar financial estimates
Financial estimateRevenue estimate
Valuation estimate
UniPhar leadership team
Management profileNumber of profiles
Profiles13 records
UniPhar subsidiaries and ownership
Company hierarchySubsidiaries13 records
UniPhar funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UniPhar M&A and investment
M&A and investmentM&A13 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UniPhar
What does UniPhar do?
UniPhar is a diversified healthcare services group distributing pharmaceutical products and medical devices across Europe, North America, APAC, and MENA. The company operates three core divisions: Uniphar Medtech (exclusive medical device distribution across 21 European markets), Uniphar Pharma (clinical trial supply, expanded access programs, and global pharma services), and Supply Chain + Retail (Irish wholesale pharmaceutical distribution and a network of 445+ retail pharmacies operating under the Allcare, Hickey's, McCauley, and Life brands).
Is UniPhar a public or private company?
UniPhar is a public company. It is classified as public and is currently operating.
When was UniPhar founded?
UniPhar was founded in 1994. It employs 1,001 to 5,000 people.
Where is UniPhar based?
UniPhar is headquartered in Dublin, Ireland, in the Europe region.
How does UniPhar make money?
Three revenue lines are on record. Pharma & Medtech Distribution is the primary driver. The others are retail Pharmacy Services and product Access & Clinical Services.
Who are UniPhar's main competitors?
Direct peers on record are Celesio / McKesson Europe, Phoenix Group, Alliance Healthcare (Walgreens Boots Alliance), IQVIA and PCI Pharma Services. Broad incumbents are McKesson Corporation, Cencora (formerly AmerisourceBergen), Walgreens Boots Alliance, Cardinal Health and Henry Schein.
Does UniPhar have an API?
No public API is recorded for UniPhar.
What industry is UniPhar in?
UniPhar's product category is Pharmaceutical and Healthcare Distribution Services. Its primary akta.pro industry code is CRAOAHAK, Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops), with a secondary code of HLAFALAA, Retail & Community Pharmacies (Chain/Independent). Its NAICS code is 42421 and its SIC code is 5122.